
Proceedings of the WFH’s Eleventh Global Forum on Research and Treatment Products for Bleeding Disorders
A summary of discussions held at the Eleventh WFH Global Forum on Research and Treatment Products for Bleeding Disorders which
Year: 2016
Language: English
This resource is also available in: Arabic French Russian Spanish Simplified Chinese
Author(s): World Federation of Hemophilia
Format: Document
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).

A summary of discussions held at the Eleventh WFH Global Forum on Research and Treatment Products for Bleeding Disorders which

This resource has also been translated into the following languages, with permission from the WFH, by NMOs/Other Organizations: German Many

Listen to this 2-hour webinar presented on April 22, 2021 to learn about global topics related to bleeding disorders. The

Adapted from: Global NMO Training 2018 plenary presentation by Glenn Pierce Reviewed by: Glenn Pierce Edited by: Georghia Michael The

Adapted from: Global NMO Training 2016 plenary presentation by Glenn Pierce Reviewed by: Glenn Pierce Edited by: Georghia Michael This

In the Monday morning session entitled Inhibitors: Clinical Aspects, Henry Daniell presents current advances in the development of new, affordable